Eton Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Eton Pharmaceuticals Inc. following an internal realignment.
NASDAQ
The Vanguard Group has reported a 5.01% beneficial ownership stake in Eton Pharmaceuticals Inc., holding over 1.3 million shares.
NASDAQ
BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.7% of Eton Pharmaceuticals, Inc.'s Common Stock as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: EcoR1 Capital and Oleg Nodelman Disclose Significant 7.7% Stake in Eton Pharmaceuticals
EcoR1 Capital, LLC and its affiliates, including Oleg Nodelman, have disclosed a 7.7% beneficial ownership stake in Eton Pharmaceuticals, Inc. as of December 31, 2024, held for investment purposes.